Oct 31, 2024 / 04:00PM GMT
Martin Welschof - BioInvent International AB - Chief Executive Officer
Welcome everybody to our interim report. And today myself the CEO Martin Welschof; as well as Stefan will give you a status where the company is and hopefully get across the very compelling status that the company at the moment has and I will jump right into the situation.
So on this slide, we summarize the activities that we had and I will start immediately with the news as you probably also have seen from the report this morning. So we have additional positive data for our lead compound 6 targeting [epsi gamma] to be especially for the subcutaneous formulation. And I will get back to more details there later.
And this, I think is a very nice example for our progress. So we had good data that we presented at AHA where we saw four responders out of four patients. And now we have additional complete response and partial responses and stable diseases, which is actually very good. And that was actually also the reason why we immediately pushed ahead with our subcu in our triplet combination. But I will come back to that
Q3 2024 BioInvent International AB Earnings Call Transcript
Oct 31, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers